References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality world-wide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. google scholar
• Dong Y, Shi O, Zeng Q, et al. Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. Exp Hematol Oncol. 2020;9:14. doi: 10.1186/s40164-020-00170-6. google scholar
• Levine R, Loriaux M, Huntly B, et al. The JAK2V617F activat-ing mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005;106(10):3377-3379. google scholar
• Lagunas-Rangel FA, Chavez-Valencia V, Gomez-Guijosa M, Cortes-Penagos C. Acute myeloid leukemia-genetic alterations and their clinical prognosis. Int J Hematol Oncol Stem Cell Res. 2017;11(4):328-339. google scholar
• Sampaio MM, Santos MLC, Marques HS, et al. Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review. World J Clin Oncol. 2021;12(2):69-94. google scholar
• Mughal T, Goldman J. Chronic myeloid leukemia: Why does it evolve from chronic phase to blast transformation? Front Biosci. 2006;11(1):198-208. google scholar
• Roskoski R, Jr. Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myeloge-nous leukemia. Pharmacol Res. 2022;178:106156. doi: 10.1016/j.phrs.2022.106156. google scholar
• Li Y, Zeng P, Xiao J, Huang P, Liu P. Modulation of energy metabolism to overcome drug resistance in chronic myeloid leukemia cells through induction of autophagy. Cell Death Discov. 2022;8(1):212. doi: 10.1038/s41420-022-00991-w. google scholar
• Gleixner KV, Filik Y, Berger D, et al. Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 (T315I)-compound mutations. Am J Cancer Res. 2021;11(9):4470-4784. google scholar
• Perez-Lamas L, Luna A, Boque C, et al. Toxicity of asciminib in real clinical practice: Analysis of side effects and cross-toxicity with tyrosine kinase inhibitors. Cancers. 2023;15(4):1045. doi:10.3390/cancers15041045 google scholar
• Merkulova A, Mitchell SC, Stavrou EX, Forbes GL, Schmaier AH. Ponatinib treatment promotes arterial thrombosis and hy-peractive platelets. Blood Adv. 2019;3(15):2312-2316. google scholar
• Pan SY, Nie Q, Tai HC, et al. Tea and tea drinking: China’s outstanding contributions to the mankind. Chin Med. 2022;17(1):27. doi: 10.1186/s13020-022-00571-1. google scholar
• Bange E, Timlin C, Kabel C, et al. Evidence for and against green tea and turmeric in the management of chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2018;18(10):e421-e6. doi: 10.1016/j.clml.2018.06.021. google scholar
• Calgarotto A, Pericole FV, Favaro P, et al. Green tea in acute myeloid leukemia. Blood. 2013;122(21):5032. doi: 10.1182/blood.V122.21.5032.5032 google scholar
• Nguyet Hai Ninh L, Luong V, Nguyen Van C, et al. An updated checklist of Theaceae and a new species of Polyspora from Vietnam. Taiwania. 2020;65(2):216-227. google scholar
• Quan N, Ly B, Chi H. The cytotoxic effect of Vernonia amyg-dalina Del. extract on myeloid leukemia cells. Biomed Res Ther. 2023;10(8):5855-5863. google scholar
• Nakazato T, Ito K, Ikeda Y, Kizaki M. Green tea compo-nent, catechin, induces apoptosis of human malignant B cells via production of reactive oxygen species. Clin Cancer Res. 2005;11(16):6040-6049. google scholar
• Er S, Dikmen M. Camellia sinensis increased apoptosis on U2OS osteosarcoma cells and wound healing potential on NIH3T3 fibroblast cells. Cytotechnology. 2017;69(6):901-914. google scholar
• Gao X, Li X, Ho C-T, et al. Cocoa tea (Camellia ptilophylla) induces mitochondria-dependent apoptosis in HCT116 cells via ROS generation and PI3K/Akt signaling pathway. Food Res Int. 2020;129:108854. doi: 10.1016/j.foodres.2019.108854. google scholar
• He D, Wang N, Sai X, Li X, Xu Y. Camellia euphlebia pro-tects against corticosterone-induced apoptosis in differentiated PC12 cells by regulating the mitochondrial apoptotic pathway and PKA/CREB/BDNF signaling pathway. Food Chem Toxicol. 2019;126:211-222. google scholar
• He X, Li H, Zhan M, et al. Camellia nitidissima chi extract potentiates the sensitivity of gastric cancer cells to paclitaxel via the induction of autophagy and apoptosis. OncoTargets Ther. 2019;12:10811-10825. google scholar
• Xuan N, Tin S, Trung P, Chi H, Ly B. Investigate the anti-cancer effects of Camellia kissi methanol extract on K562 Leukemia cells. JST-UD. 2023;21(5):73-77. google scholar
• Janicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem. 1998;273(16):9357-9360. google scholar
• Matassov D, Kagan T, Leblanc J, Sikorska M, Zakeri Z. Mea-surement of apoptosis by DNA fragmentation. Methods Mol Biol (Clifton, NJ). 2004;282:1-17. google scholar
• Chen L, Chen J, Xu H. Sasanquasaponin from Camellia oleifera Abel. induces cell cycle arrest and apoptosis in human breast cancer MCF-7 cells. Fitoterapia. 2013;84:123-129. google scholar
• Wang Y, Ren N, Rankin GO, et al. Anti-proliferative effect and cell cycle arrest induced by saponins extracted from tea (Camellia sinensis) flower in human ovarian cancer cells. J Funct Foods. 2017;37:310-321. google scholar
• Steelman LS, Pohnert SC, Shelton JG, et al. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progres-sion and leukemogenesis. Leukemia. 2004;18(2):189-218. google scholar
• Morotti A, Panuzzo C, Crivellaro S, et al. BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phos-phorylation. Cell cycle (Georgetown, Tex). 2015;14(7):973-979. google scholar
• Li XX, Liu C, Dong SL, et al. Anticarcinogenic poten-tials of tea catechins. Front Nutr. 2022;9:1060783. doi: 10.3389/fnut.2022.1060783. google scholar
• Iwasaki R, Ito K, Ishida T, et al. Catechin, green tea component, causes caspase-independent necrosis-like cell death in chronic myelogenous leukemia. Cancer Sci. 2009;100(2):349-356. google scholar
• Massimino M, Stella S, Tirro E, et al. Non ABL-directed in-hibitors as alternative treatment strategies for chronic myeloid leukemia. Mol Cancer2018;17(1):56. doi: 10.1186/s12943-018-0805-1. google scholar
• Fisher D, Krasinska L. Explaining redundancy in CDK-mediated control of the cell cycle: Unifying the continuum and quantitative models. Cells. 2022;11(13):2019. doi: 10.3390/cells11132019. google scholar
• Rizzotto D, Englmaier L, Villunger A. At a crossroads to cancer: How p53-induced cell fate decisions secure genome integrity. Int JMol Sci. 2021;22(19):10883. doi: 10.3390/yms221910883. google scholar

Citations